PTPRC and neoplasm: We analyzed the status of central immune activity using immunophenotyping of splenocytes (CD45+, CD8+, and CD4+ cell counting) and observed similar levels of CD45+ cells in all groups, suggesting immune activated statuses against tumor cells.